Mymetics Corp (MYMX)

[TheHungryHippo]

Correction, DD says that would be 200 Million+..

"GSK has invested more than $365 million to date and expects to invest a further $200 to $250 million until development is completed. Between 2001 and the end of 2014, the MVI, supported by grants from Bill & Melinda Gates Foundation, invested more than $200 million to advance the RTS,S project."

RTS,S is the most advanced malaria vaccine candidate in development globally. It was created in 1987 by scientists working at GSK laboratories. Early clinical development was done in collaboration with the Walter Reed Army Institute for Research. In January 2001, GSK and PATH, with grant monies from the Bill & Melinda Gates Foundation to PATH, entered into a public-private partnership to develop an RTS,S-based vaccine for infants and young children living in malaria-endemic regions in sub-Saharan Africa.

GLAXO SMITH KLINE

GSK NYSE: trading at $40.58,

MOSQUIRIX or RTS-S Vaccine

http://www.malariavaccine.org/sites/www.malariavaccine.org/files/content/page/files/RTSS%20FAQs_FINAL.pdf

http://www.malariavaccine.org/malaria-and-vaccines/first-generation-vaccine/rtss

RTS,S is an injectable vaccine that provides partial protection against malaria in young children. Like vaccines generally, RTS,S aims to trigger the body’s own immune system to defend against disease, in this case, malaria caused by Plasmodium falciparum, the most deadly species of the malaria parasite globally and the most prevalent in Africa. The large-scale Phase 3 efficacy and safety trial of RTS,S (which concluded in January 2014) showed that the vaccine candidate could provide meaningful public health benefit by reducing the burden of malaria when used alongside currently available interventions such as bednets and insecticides.


PATH and Walter Reed Army Institute of Research announce largest-ever controlled malaria infection study

8 SEP 2017

Washington, DC, and Silver Spring, MD (8 September 2017)—PATH’s Malaria Vaccine Initiative (MVI) and the US Department of Defense’s Walter Reed Army Institute of Research (WRAIR) announced today that vaccinations are under way in a clinical trial to evaluate modifications to the vaccine regimen of GSK’s RTS,S/AS01 (RTS,S) malaria vaccine candidate. The partners seek to understand if these modifications will provide equal or increased protection compared to the standard pediatric regimen.



SO... MOSQUIRIX IS DELIVERED THROUGH INJECTION, therefore still required to be in the cold chain of vaccine preservation, which mymetics seeks to improve upon with their VIROSOME technology.

What if, Bill and Melinda decided that they would want to fund a large study with the MYMX Virosomes through PATH MVI ?

I found SIGNIFICANT evidence that this is something they are searching for, and why I believe that it is possible for a MAJOR round of funding for our Malaria Vaccine Candidate;

Although we continue to see more investments and funding into GSK's "MOSQUIRIX" (RTS-S)

We find this article in 2015 that states the disappointments of RTS-S:

An experimental malaria vaccine the Bill & Melinda Gates Foundation had long championed and that many had characterized as the ‘most promising’ such vaccine, a critical tool for moving us closer to Bill Gates’ goal of eradication, has shown disappointing results.


Five years ago, many in the malaria field believed eradication would be “impossible” without an effective vaccine. However, Bill Gates’ 2015 annual letter proposed dispatching malaria “within a generation,” not through vaccination but mass screening and drug administration. In it, Gates relegated vaccines from the front lines to a mop up role, less protecting people from malaria than preventing further transmission in the event of infection, “so that once an area is cleared of the parasite, it stays clear.” Vaccines are much fallen.

SO... Gates realized it was more about transmission blocking, than prevention.

Why not have the best of both worlds?

So who has a Transmission blocking Malaria Vaccine already in a public-private agreement with PATH MVI?

Thats right, MYMETICS.

Mymetics’ proprietary virosome technology platform and its specialist virosome know-how has been selected to develop an innovative Malaria transmission-blocking vaccine candidate in partnership with the Laboratory of Malaria Immunology and Vaccinology (LMIV) of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

If this study is successful, the next step could be to prepare for clinical trials for a malaria transmission-blocking virosome vaccine and also explore the possibilities to combine this vaccine with other malaria vaccine candidates which are focused on other aspects of preventing malaria. Mymetics has shown separately in 2011 in a privately funded Phase 1b clinical trial in Tanzania that a virosome based vaccine for Plasmodium falciparum could reduce malaria episodes in children by more than 50% 1).

http://www.biospace.com/News/mymetics-corporation-announces-new-collaboration/355269

From Mymetics website it states the results of the Preclinical Testing with MYMX's Malaria Vaccine:

"The first initial results from the study showed that the virosome vaccine candidates, at the highest dose tested, generate high antibody titers against the required antigens and they were able to significantly reduce (97-100%) the transmission of the Plasmodium falciparum parasite.

Mymetics is currently evaluating funding opportunities for further development of the vaccine candidates."
[/I]

http://www.mymetics.com/vaccine-pipeline/malaria/


NOW WE GET THIS COMMENT from the MACIVIVA report summary, which is testing MYMX virosomes in a totally separate project:

"Due to superior stability and the ease of administration of future solid vaccine forms for non-invasive routes, the world vaccine market landscape is expected to change. Thermostable solid vaccine forms developed for needle-free mucosal administration are expected to gradually replace the liquid and lyophilized/reconstituted vaccines administered by needle/syringe injections. Thus, such new thermostable solid vaccines will contribute to higher immunization coverage for the great benefit of the overall health care system. If successful, the thermostable vaccines will be also highly attractive for the Bill & Melinda Gates Foundation (BMGF), Malaria Vaccine Initiative-PATH (MVI-PATH) and the World Health Organization (WHO) that are all in favor of novel affordable vaccines with improved stability under warm conditions."

http://cordis.europa.eu/result/rcn/194900_en.html

Sanofi was recently embarrassed by Walter Reed when they CUT FUNDING for their influenza Vaccine testing and publicly accused Sanofi of wanting to do price gouging ? and then a day later come out with a collaboration on the worlds largest clinical trial with GSK and Mosquirix ?

Sounds to me like the latest press release about the MACIVIVA project containing "promising" results.. could have more implications than meets the eye. The combination of Thermostability and Transmission blocking VACCINE is what the PATH MVI initiative seek to eradicate Malaria once and for all, and exactly what Mymetics has to offer.

Sounds to me like Gates could already be on top of this.. or better yet, why would Sanofi allow GSK and Walter reed to take the lead on Malaria, when they could just outright purchase all of Mymetics, after all the testing being done is comparing virosomes to egg based vaccines. Something tells me that Sanofi may want to make a buyout offer soon, and that if they controlled the Virosome technology, they will be able to, along with PATH MVI, and Bill Gates, completely eradicate Malaria from the face of the earth and crush the competition of GSK in the World's Vaccine market.

AND. Make us a shit load of money.

NOW WHERE'S THAT FUNDING PR? and or BUYOUT! ?

The purpose of the project MACIVIVA is to develop Vaccine based tablets that are not required to be put in cold storage so that they can have longer storage life and be transferred and delivered around the world efficiently.

freeze dried zydis tablets are designed to store a manufactured vaccine which dissolves on the human tongue within 3 seconds.

Mymetics is the partner that is required in Maciviva to produce the virosome membranes. They have developed the virosome to be completely able to be packaged into freeze dried soluble tablets.

Catalent (NYSE) is another partner on the Maciviva project... they are responsible for the tablets..

but none of which is possible without Mymetics virosome membranes.. These membranes are able to "DELIVER" the vaccine to the human effectively.

http://www.catalent.com/index.php/news-events/news/Catalent-Awarded-Grant-As-Part-Of-Vaccine-Research-Consortium

"No More Pricks"

http://www.maciviva.eu